Jessica L Goren, Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clozapine | 6 | 2018 | 509 | 2.040 |
Why?
|
| Antipsychotic Agents | 12 | 2018 | 3078 | 1.400 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 937 | 0.810 |
Why?
|
| Polypharmacy | 2 | 2013 | 307 | 0.610 |
Why?
|
| Pharmacists | 2 | 2016 | 261 | 0.500 |
Why?
|
| Schizophrenia | 7 | 2017 | 6977 | 0.490 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 395 | 0.440 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 271 | 0.420 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 939 | 0.390 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 225 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 2174 | 0.300 |
Why?
|
| Schools, Pharmacy | 1 | 2007 | 5 | 0.290 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 881 | 0.280 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2007 | 134 | 0.260 |
Why?
|
| Bacterial Infections | 1 | 2014 | 1390 | 0.250 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2013 | 1567 | 0.240 |
Why?
|
| Fructose | 1 | 2006 | 284 | 0.230 |
Why?
|
| Hyperthyroidism | 1 | 2006 | 292 | 0.230 |
Why?
|
| Psychiatric Department, Hospital | 2 | 2018 | 133 | 0.230 |
Why?
|
| Psychiatry | 1 | 2016 | 1715 | 0.220 |
Why?
|
| Psychotic Disorders | 3 | 2018 | 3275 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5537 | 0.210 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2011 | 1399 | 0.190 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 1512 | 0.170 |
Why?
|
| Yawning | 1 | 1998 | 6 | 0.150 |
Why?
|
| Dibenzothiazepines | 1 | 1998 | 102 | 0.150 |
Why?
|
| Bupropion | 1 | 2000 | 303 | 0.150 |
Why?
|
| Levodopa | 1 | 1998 | 221 | 0.140 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2000 | 491 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3700 | 0.130 |
Why?
|
| Bipolar Disorder | 3 | 2018 | 5130 | 0.130 |
Why?
|
| Inflammation | 1 | 2014 | 10869 | 0.110 |
Why?
|
| Piracetam | 1 | 2011 | 88 | 0.090 |
Why?
|
| Medicare Part C | 1 | 2014 | 333 | 0.080 |
Why?
|
| Multi-Institutional Systems | 1 | 2007 | 43 | 0.070 |
Why?
|
| Massachusetts | 3 | 2010 | 8890 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2014 | 6310 | 0.060 |
Why?
|
| Humans | 20 | 2018 | 767040 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 1664 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 829 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 2 | 2004 | 317 | 0.060 |
Why?
|
| Professional Role | 1 | 2007 | 315 | 0.060 |
Why?
|
| Chlorpromazine | 1 | 2004 | 111 | 0.060 |
Why?
|
| United States | 4 | 2016 | 72971 | 0.060 |
Why?
|
| Faculty | 1 | 2007 | 383 | 0.060 |
Why?
|
| Parkinson Disease | 1 | 1998 | 2886 | 0.060 |
Why?
|
| Relaxation | 1 | 2003 | 51 | 0.050 |
Why?
|
| Mental Disorders | 3 | 2011 | 6873 | 0.050 |
Why?
|
| S-Adenosylmethionine | 1 | 2003 | 219 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2016 | 5098 | 0.050 |
Why?
|
| Critical Care | 1 | 2014 | 2714 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2011 | 1921 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 1467 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 2783 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2013 | 6409 | 0.040 |
Why?
|
| Sialorrhea | 1 | 2018 | 25 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2011 | 3446 | 0.040 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 2912 | 0.040 |
Why?
|
| Male | 11 | 2018 | 364203 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2010 | 3467 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2002 | 1190 | 0.030 |
Why?
|
| Epilepsy | 1 | 2011 | 3317 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 1263 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 10393 | 0.030 |
Why?
|
| Hospitals | 1 | 2007 | 3883 | 0.030 |
Why?
|
| Middle Aged | 5 | 2014 | 223233 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 892 | 0.030 |
Why?
|
| Hospitalization | 2 | 2010 | 10815 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2003 | 2906 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2002 | 10748 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2007 | 4746 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4091 | 0.020 |
Why?
|
| Female | 7 | 2018 | 396660 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2018 | 81659 | 0.020 |
Why?
|
| Adult | 6 | 2013 | 223317 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 89046 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2003 | 4813 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 4855 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2232 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 2003 | 259 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 8048 | 0.010 |
Why?
|
| Phosphorus | 1 | 2003 | 336 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2000 | 39317 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 1987 | 0.010 |
Why?
|
| Age Factors | 1 | 2014 | 18401 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 2001 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 27163 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10582 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 4026 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 3684 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2003 | 2672 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 26325 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 8535 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1998 | 65295 | 0.010 |
Why?
|
| Child | 1 | 2018 | 80771 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 9464 | 0.000 |
Why?
|
| Aged | 2 | 2014 | 171319 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2004 | 22254 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2004 | 24299 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 59548 | 0.000 |
Why?
|
| Risk Factors | 1 | 2004 | 74886 | 0.000 |
Why?
|